Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical Clinical Trials

Novartis Ups Ante In Acromegaly Injectables As Oral Contender Emerges

This article was originally published in Pharmaceutical Approvals Monthly

  • News

Executive Summary

Novartis gears up to file new injectable pasireotide LAR by the end of 2012 for the niche acromegaly market, ahead of the patent expiration of its blockbuster Sandostatin LAR. But Israeli biotech Chiasma is hoping to deliver an oral option with Octreolin.

You may also be interested in...



Deals Of The Week Wonders: What Does Merck’s Latest Biosimilar Move Really Mean?

Plus a look at Roche/Chiasma, Chiesi/Cornerstone, Eisai/Valeant and more

Roche Buys Rights To Market Chiasma’s Acromegaly Pill Octreolin

Roche is betting Chiasma’s daily oral drug Octreolin will prove a winner for treating orphan disease acromegaly and hopes the Israel-based biotech’s underlying Transient Permeability Enhancer technology can be used to develop other oral drugs that previously were only available by injection.

Pharmacia Somavert Clears FDA For Acromegaly; Liver Testing Recommended

Labeling for Pharmacia's acromegaly treatment Somavert recommends monthly liver function monitoring for the first six months of treatment

Table

View full table

Topics

Related Companies

Tags:
BioPharmaceutical Clinical Trials
Latest Headlines

US FDA’s October Outlook: Xphozah After Dispute, Santhera’s New Steroid For DMD, & Plenty Of Pfizer

Can Medicare Cover Obesity Drugs Without Congressional Action? Industry Builds Its Case

Pink Sheet Podcast: Adcomm Rejects NurOwn For ALS, FDA In Shutdown Mode, Limited Price Negotiation Savings

Increase In Subpar Pharmaceutical Repacking Draws US FDA Attention

See All
UsernamePublicRestriction

Register

PS004990

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By